Skip to content
Search

Latest Stories

Spring budget brings no obvious good news for community pharmacies: Janet Morrison

Spring budget brings no obvious good news for community pharmacies: Janet Morrison

RPS England Chair Tase Oputu urged the government and NHS to focus on accelerating the adoption of electronic prescribing in hospitals.  

Community Pharmacy England (CPE) has expressed dissatisfaction with the spring budget as it bringsno specific relief” for the community pharmacy sector, which is grappling with “soaring costs and severe medicine supply and pricing issues.”


UK Chancellor Jeremy Hunt announced his Spring Budget on Wednesday, confirming an extra £2.5 billion in day-to-day revenue funding for the NHS in England in 2024–25 and a new NHS productivity plan worth £3.4bn to modernise IT systems.

The Chancellor said that day-to-day spending would grow by 1 per cent per year on average in real terms, and the productivity plan is estimated to “unlock £35 billion worth of savings” from 2025-26 to 2029-30.

However, CPE chief executive, Janet Morrison commented that the budget has “no obvious good news” for community pharmacies who need “urgent relief from the ongoing unsustainable funding and operational pressures” they are facing.

Morrison described the investment in Pharmacy First as “the most significant investment in pharmacies in a decade”, but emphasised the need for further support to stabilise the sector and its core contractual arrangements.

“If the one per cent annual growth in day-to-day NHS spending is applied across primary care this will do little to fill pharmacy’s core funding gap.

“And while the NHS productivity plans may theoretically add some efficiencies across primary care, it remains to be seen if this will bring any real benefit to pharmacies: the devil will be in the detail, and this will not provide the silver bullet that pharmacies so desperately need,” she said.

Morrison reiterated that further investment in community pharmacies would be good for businesses, high-streets, patients, the public and the wider NHS.

She also warned the NHS and government of the devastating consequences if they continue to allow pharmacies to close.

Tase Oputu, Chair of the Royal Pharmaceutical Society (RPS) England, welcomed the proposed NHS productivity plan, but she said it should also focus on “accelerating the adoption of electronic prescribing in hospitals”, alongside universal electronic patient records and transfers of care.

“The roll-out of Pharmacy First has also shown just how important it is for pharmacists to be able to update a clinical record wherever they work and it is vital this is achieved as soon as possible.

“Efforts to reduce the time frontline workers spend on administrative tasks should consider steps to address the increasing amount of time that pharmacists and GPs spend managing medicines shortages,” she said.

She urged the government and NHS to provide greater clarity on the next steps for the NHS Long-Term Workforce plan and how it will support recruitment and retention.

Oputu suggested that the workforce plan should include enabling pharmacy students to access the Learning Support Fund alongside other health professions.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less